SCHEMBL17834328

SCHEMBL17834328

N#Cc1ccccc1CN1C(=O)SC(=Cc2ccc(Sc3nc4ccccc4[nH]3)o2)C1=O

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
SMN1; SMN2 Q16637 4/20 0.73
HPGD P15428 2/20 0.73
ALDH1A1 P00352 3/20 0.71
LMNA P02545 3/20 0.71
MAPT P10636 2/20 0.71
MAPK1 P28482 2/20 0.71
MYC P01106 16/20 0.68
HTT P42858 2/20 0.63
KDM4E B2RXH2 1/20 0.62
CYP1A2 P05177 1/20 0.62
GLA P06280 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834317 0.88 MEN1 (0.74) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834253 0.84 MEN1 (1.00) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834351 0.84 MEN1 (1.00) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834252 0.84 MEN1 (0.79) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834332 0.83 MEN1 (1.00) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834257 0.83 MEN1 (1.00) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834350 0.82 MEN1 (0.76) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17821432 0.82 MYC (0.84) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17821427 0.82 MYC (0.84) MEN1KMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL17834346 0.81 MYC (0.86) MEN1KMT2ASMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017520-B2 Myc modulators and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-07-10 US disclosed
US-20160168165-A1 MYC MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-16 US disclosed
WO-2016094688-A1 FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168165-A1 MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 MEN1 336/4885KMT2A 1253/4885SMN1; SMN2 4149/4885
US-10017520-B2 Myc modulators and uses thereof MYC, MYCBP, MYCBP2 MEN1 336/4885KMT2A 1253/4885SMN1; SMN2 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.